A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650
This study is recruiting at 52 US sites in 25 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypothesis is that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to overall survival (OS), in androgen receptor ligand binding domain (AR LBD) mutation positive and negative participants.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Prostatic Neoplasms
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- The University of Arizona Cancer Center - North Campus ( Site 0073) · Tucson, AZ
California · 7
- CHAO Family Comprehensive Cancer Center and Ambulatory Care ( Site 0120) · Irvine, CA
- UCLA Hematology/Oncology - Santa Monica ( Site 0044) · Los Angeles, CA
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040) · Orange, CA
- Stanford Cancer Center ( Site 0036) · Palo Alto, CA
- Kaiser Permanente Riverside Medical Center ( Site 0099) · Riverside, CA
- University of California Davis (UC Davis) Comprehensive Cancer Center ( Site 0114) · Sacramento, CA
- San Francisco VA Health Care System ( Site 0093) · San Francisco, CA
Colorado · 4
- University of Colorado Anschutz Medical Campus ( Site 0046) · Aurora, CO
- UCHealth Highlands Ranch Hospital ( Site 0111) · Highlands Ranch, CO
- Colorado Clinical Research ( Site 0067) · Lakewood, CO
- University of Colorado Health - Lone Tree Medical Center ( Site 0112) · Lone Tree, CO
Connecticut · 1
- Yale-New Haven Hospital-Yale Cancer Center ( Site 0064) · New Haven, CT
District of Columbia · 1
- MedStar Washington Hospital Center ( Site 0103) · Washington D.C., DC
Florida · 2
- Mount Sinai Braman Comprehensive Cancer Center ( Site 0107) · Miami Beach, FL
- Memorial Hospital West-Memorial Cancer Institute ( Site 0109) · Pembroke Pines, FL
Illinois · 1
- Illinois Cancer Care ( Site 0104) · Peoria, IL
Indiana · 1
- Urology of Indiana - Carmel ( Site 0055) · Carmel, IN
Maryland · 3
- Baltimore Veterans Affairs Medical Center ( Site 0069) · Baltimore, MD
- Greenebaum Comprehensive Cancer Center ( Site 0049) · Baltimore, MD
- Chesapeake Urology ( Site 0009) · Towson, MD
Michigan · 2
- Henry Ford Hospital ( Site 0015) · Detroit, MI
- Cancer and Hematology Centers of Western Michigan ( Site 0005) · Grand Rapids, MI
Minnesota · 3
- Avera Cancer Institute - Marshall ( Site 0122) · Marshall, MN
- HealthPartners Cancer Research Center-HealthPartners Frauenshuh Cancer Center ( Site 0072) · Saint Louis Park, MN
- HealthPartners Cancer Research Center-HealthPartners Cancer Center at Regions Hospital ( Site 0092) · Saint Paul, MN
Montana · 1
- St. Vincent Frontier Cancer Center-Research ( Site 0037) · Billings, MT
Nebraska · 1
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0026) · Omaha, NE
Nevada · 2
- Comprehensive Cancer Centers of Nevada ( Site 0010) · Las Vegas, NV
- OptumCare Cancer Care-Research Department ( Site 0078) · Las Vegas, NV
New Jersey · 1
- Rutgers Cancer Institute of New Jersey ( Site 0033) · New Brunswick, NJ
New York · 1
- Associated Medical Professionals - Urology ( Site 0081) · Syracuse, NY
Ohio · 1
- University Hospitals Cleveland Medical Center ( Site 0043) · Cleveland, OH
Pennsylvania · 2
- MidLantic urology ( Site 0022) · Bala-Cynwyd, PA
- Fox Chase Cancer Center ( Site 0076) · Philadelphia, PA
South Carolina · 1
- Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083) · Charleston, SC
South Dakota · 5
- Avera Cancer Institute - Aberdeen ( Site 0123) · Aberdeen, SD
- Avera Cancer Institute - Mitchell ( Site 0121) · Mitchell, SD
- Avera Cancer Institute - Pierre ( Site 0118) · Pierre, SD
- Avera Cancer Institute- Research ( Site 0094) · Sioux Falls, SD
- Avera Cancer Institute - Yankton ( Site 0117) · Yankton, SD
Tennessee · 1
- The West Clinic, PLLC dba West Cancer Center ( Site 0063) · Germantown, TN
Texas · 3
- Texas Oncology - Central/South Texas ( Site 8003) · Austin, TX
- Texas Oncology - DFW ( Site 8001) · Dallas, TX
- Texas Oncology - Gulf Coast ( Site 8002) · Houston, TX
Virginia · 5
- University of Virginia Health System ( Site 0054) · Charlottesville, VA
- Inova Schar Cancer Institute ( Site 0017) · Fairfax, VA
- Virginia Cancer Specialists (VCS) ( Site 8004) · Fairfax, VA
- VCU Health Adult Outpatient Pavillion ( Site 0061) · Richmond, VA
- Blue Ridge Cancer Care ( Site 0004) · Roanoke, VA
Washington · 1
- Spokane Urology ( Site 0035) · Spokane, WA
Wisconsin · 1
- Medical College of Wisconsin ( Site 0020) · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.